Skip to main content
SpringerLink
Log in

Brexpiprazole prevents schizophrenia relapse at lower cost

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. Editorial support for this study was funded by Otsuka America Pharmaceutical Inc. and Lundbeck LLC, USA.

Reference

  • Aigbogun MS, et al. Relapse prevention: a cost-effectiveness analysis of brexpiprazole treatment in adult patients with schizophrenia in the USA. ClinicoEconomics and Outcomes Research : 16 Aug 2018. Available from: URL: https://doi.org/10.2147/CEOR.S160252

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Brexpiprazole prevents schizophrenia relapse at lower cost. PharmacoEcon Outcomes News 810, 3 (2018). https://doi.org/10.1007/s40274-018-5194-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-018-5194-6

Search

Navigation